PubTransformer

A site to transform Pubmed publications into these bibliographic reference formats: ADS, BibTeX, EndNote, ISI used by the Web of Knowledge, RIS, MEDLINE, Microsoft's Word 2007 XML.

Antitumor Effects of Lidocaine on Human Breast Cancer Cells: An In Vitro and In Vivo Experimental Trial.

Abstract Retrospective studies have suggested a protective effect of regional anesthesia against recurrence after cancer surgery. But confirmation of the in vivo antitumor effects is lacking. We examined the in vitro antitumor effects of lidocaine on various breast cancer cell lines and then assessed these properties in vivo at clinically relevant concentrations.
PMID
Related Publications

The quinoxaline di-N-oxide DCQ blocks breast cancer metastasis in vitro and in vivo by targeting the hypoxia inducible factor-1 pathway.

Targeting triple-negative breast cancer cells with the histone deacetylase inhibitor panobinostat.

The role of the polyamine catabolic enzymes SSAT and SMO in the synergistic effects of standard chemotherapeutic agents with a polyamine analogue in human breast cancer cell lines.

Antitumor activity of phenethyl isothiocyanate in HER2-positive breast cancer models.

Local anesthetics induce apoptosis in human breast tumor cells.

Authors

Mayor MeshTerms
Keywords

Local anesthetics

MDA-MB-231 cell line

breast cancer

lidocaine

xenograft model antitumor assays

Journal Title anticancer research
Publication Year Start




PMID- 29277761
OWN - NLM
STAT- MEDLINE
DCOM- 20180101
LR  - 20180101
IS  - 1791-7530 (Electronic)
IS  - 0250-7005 (Linking)
VI  - 38
IP  - 1
DP  - 2018 Jan
TI  - Antitumor Effects of Lidocaine on Human Breast Cancer Cells: An In Vitro and In
      Vivo Experimental Trial.
PG  - 95-105
AB  - AIM: Retrospective studies have suggested a protective effect of regional
      anesthesia against recurrence after cancer surgery. But confirmation of the in
      vivo antitumor effects is lacking. We examined the in vitro antitumor effects of 
      lidocaine on various breast cancer cell lines and then assessed these properties 
      in vivo at clinically relevant concentrations. MATERIALS AND METHODS: In vitro
      experiments: normal breast epithelial cells (NBEC) MCF-10A and three tumor breast
      epithelial cells (TBEC) lines (MCF-7 luminal A, MDA-MB-231 triple-negative and
      SKBr3 HER2 positive) were exposed to increasing concentrations of lidocaine. Cell
      viability, migration and anchorage-independent growth were assessed by MTT, wound
      healing, and soft-agar growth assays. In vivo experiments: 6-week-old severe
      combined immunodeficient mice were injected intraperitoneally with MDA-MB-231
      cells and were treated with intraperitoneal lidocaine or phosphate-buffered
      saline. The mice were euthanized when they reached experimental endpoints or
      sacrificed to determine peritoneal carcinomatosis index and global tumor volumes.
      RESULTS: Lidocaine reduced the viability of all the cell lines, inhibited
      migration of TBEC compared to the NBEC, and compromised the anchorage-independent
      growth of the triple-negative cells. Intraperitoneal lidocaine improved survival 
      of mice with MDA-MB-231 peritoneal carcinomatosis using doses that are consistent
      with the current clinical settings for analgesia. CONCLUSION: In agreement with
      the notion that local anesthesia may be beneficial for cancer therapy, lidocaine 
      has a protective effect against breast cancer cells in experimental studies.
      However, the beneficial impact of local anesthetics on breast cancer needs to be 
      strengthened by additional preclinical and clinical trials.
CI  - Copyright(c) 2018, International Institute of Anticancer Research (Dr. George J. 
      Delinasios), All rights reserved.
FAU - Chamaraux-Tran, Thien-Nga
AU  - Chamaraux-Tran TN
AD  - Department of Anesthesiology and Surgical Intensive Care, Hautepierre Hospital,
      CHRU, University Hospital of Strasbourg, Strasbourg, France [email protected]
AD  - Functional Genomics and Cancer Department, Institute of Genetics and Molecular
      and Cellular Biology (IGBMC), Illkirch, France.
AD  - French National Center for Scientific Research (CNRS) UMR7104, Illkirch, France.
AD  - French National Institute of Health and Medical Research (INSERM) U964, Illkirch,
      France.
AD  - Faculty of Medicine, University of Strasbourg, Strasbourg, France.
FAU - Mathelin, Carole
AU  - Mathelin C
AD  - Functional Genomics and Cancer Department, Institute of Genetics and Molecular
      and Cellular Biology (IGBMC), Illkirch, France.
AD  - French National Center for Scientific Research (CNRS) UMR7104, Illkirch, France.
AD  - French National Institute of Health and Medical Research (INSERM) U964, Illkirch,
      France.
AD  - Faculty of Medicine, University of Strasbourg, Strasbourg, France.
AD  - Department of Gynecology and Obstetrics, Hautepierre Hospital, CHRU, University
      Hospital of Strasbourg, Strasbourg, France.
FAU - Aprahamian, Marc
AU  - Aprahamian M
AD  - Research Institute against Digestive Cancer - European Institute of TeleSurgery
      (IRCAD), Strasbourg, France.
FAU - Joshi, Girish P
AU  - Joshi GP
AD  - Department of Anesthesiology and Pain Management, University of Texas
      Southwestern Medical Center, Dallas, TX, U.S.A.
FAU - Tomasetto, Catherine
AU  - Tomasetto C
AD  - Functional Genomics and Cancer Department, Institute of Genetics and Molecular
      and Cellular Biology (IGBMC), Illkirch, France.
AD  - French National Center for Scientific Research (CNRS) UMR7104, Illkirch, France.
AD  - French National Institute of Health and Medical Research (INSERM) U964, Illkirch,
      France.
AD  - Faculty of Medicine, University of Strasbourg, Strasbourg, France.
FAU - Diemunsch, Pierre
AU  - Diemunsch P
AD  - Department of Anesthesiology and Surgical Intensive Care, Hautepierre Hospital,
      CHRU, University Hospital of Strasbourg, Strasbourg, France.
AD  - Faculty of Medicine, University of Strasbourg, Strasbourg, France.
AD  - Research Institute against Digestive Cancer - European Institute of TeleSurgery
      (IRCAD), Strasbourg, France.
FAU - Akladios, Cherif
AU  - Akladios C
AD  - Faculty of Medicine, University of Strasbourg, Strasbourg, France.
AD  - Department of Gynecology and Obstetrics, Hautepierre Hospital, CHRU, University
      Hospital of Strasbourg, Strasbourg, France.
AD  - Research Institute against Digestive Cancer - European Institute of TeleSurgery
      (IRCAD), Strasbourg, France.
LA  - eng
PT  - Journal Article
PL  - Greece
TA  - Anticancer Res
JT  - Anticancer research
JID - 8102988
RN  - 0 (Anesthetics, Local)
RN  - 0 (Antineoplastic Agents)
RN  - 98PI200987 (Lidocaine)
SB  - IM
MH  - Anesthetics, Local/pharmacology
MH  - Animals
MH  - Antineoplastic Agents/*pharmacology/*therapeutic use
MH  - Breast Neoplasms/*drug therapy/pathology
MH  - Cell Line, Tumor
MH  - Cell Movement/drug effects
MH  - Cell Survival/drug effects
MH  - Female
MH  - Humans
MH  - Lidocaine/*pharmacology/*therapeutic use
MH  - Mice, SCID
MH  - Peritoneal Neoplasms/drug therapy/pathology
OTO - NOTNLM
OT  - Local anesthetics
OT  - MDA-MB-231 cell line
OT  - breast cancer
OT  - lidocaine
OT  - xenograft model antitumor assays
EDAT- 2017/12/27 06:00
MHDA- 2018/01/02 06:00
CRDT- 2017/12/27 06:00
PHST- 2017/10/04 00:00 [received]
PHST- 2017/10/29 00:00 [revised]
PHST- 2017/11/01 00:00 [accepted]
PHST- 2017/12/27 06:00 [entrez]
PHST- 2017/12/27 06:00 [pubmed]
PHST- 2018/01/02 06:00 [medline]
AID - 38/1/95 [pii]
PST - ppublish
SO  - Anticancer Res. 2018 Jan;38(1):95-105.